Glaxo Subsidiary Stiefel’s Former CEO Faces Securities Fraud Charges
This article was originally published in The Rose Sheet
Executive Summary
The Securities and Exchange Commission alleges Charles Stiefel, former chairman and CEO of family-owned Stiefel Labs, did not disclose to employee-shareholders material information on the value of the firm’s shares as it was buying back shares before being acquired by GlaxoSmithKline.
You may also be interested in...
GSK Gains Foothold In U.S. Skin Care With Stiefel Deal
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion with the acquisition of Stiefel Laboratories, a move that provides GSK a foothold in the U.S. market for nonprescription skin-care products
Stiefel Uses Coffee Berry, Connetics Buy To Close In On Aesthetic Market
Stiefel Laboratories will enter the aesthetic dermatology market this spring with Revaleskin, an anti-aging therapy formulated from the coffee berry
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.